Detalhe da pesquisa
1.
Transcriptional re-programming of insulin B-chain epitope-specific T-follicular helper cells into anti-diabetogenic T-regulatory type-1 cells.
Front Immunol
; 14: 1177722, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37153608
2.
A T follicular helper cell origin for T regulatory type 1 cells.
Cell Mol Immunol
; 20(5): 489-511, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36973489
3.
Re-programming mouse liver-resident invariant natural killer T cells for suppressing hepatic and diabetogenic autoimmunity.
Nat Commun
; 13(1): 3279, 2022 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672409
4.
Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity.
Front Immunol
; 12: 684240, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34335585
5.
Recognition of Multiple Hybrid Insulin Peptides by a Single Highly Diabetogenic T-Cell Receptor.
Front Immunol
; 12: 737428, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34527002
6.
Extremely short bioavailability and fast pharmacodynamic effects of pMHC-based nanomedicines.
J Control Release
; 338: 557-570, 2021 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474072
7.
Liver-specific T regulatory type-1 cells program local neutrophils to suppress hepatic autoimmunity via CRAMP.
Cell Rep
; 34(13): 108919, 2021 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789099
8.
Increased yields and biological potency of knob-into-hole-based soluble MHC class II molecules.
Nat Commun
; 10(1): 4917, 2019 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31664029
9.
Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices.
Nat Nanotechnol
; 12(7): 701-710, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28436959